Lunsumio (mosunetuzumab-axgb) / Roche 
Welcome,         Profile    Billing    Logout  
 5 Diseases   9 Trials   9 Trials   228 News 


«123456789101112»
  • ||||||||||  Columvi (glofitamab-gxbm) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche, Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
    Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients With DLBCL (LEVEL 3, HALL B3) -  Aug 30, 2024 - Abstract #SOHO2024SOHO_746;    
    P1
    Increased doses of Lonca in combinations were predicted to have limited additional therapeutic benefit; however, additional cycles of combination treatment were predicted to increase TGI. This model suggests that Lonca doses could be reduced to improve tolerability for longer periods of time, up to the point of maximal benefit, although clinical testing is needed to explore these results.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
    Enrollment open, Trial completion date, Trial primary completion date:  Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grade 1-3a Follicular Lymphoma (clinicaltrials.gov) -  Aug 14, 2024   
    P2,  N=41, Recruiting, 
    Findings from this study show improved efficacy and more durable response for the treatment of 3L+ R/R FL with axi-cel relative to mosunetuzumab, with increased odds of all-grade CRS and NE, but not G3+ CRS and TRAEs. Not yet recruiting --> Recruiting | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2027 --> Mar 2028
  • ||||||||||  Lunsumio (mosunetuzumab-axgb) / Roche
    New P2 trial:  GELLC-9Richter: M-CHOP in Richter (clinicaltrials.gov) -  Jul 25, 2024   
    P2,  N=34, Recruiting, 
  • ||||||||||  Approach to Untreated Follicular Lymphoma, Where Are We Now and Future Directions (LEVEL 3, GENERAL ASSEMBLY) -  Jul 5, 2024 - Abstract #SOHO2024SOHO_228;    
    Not yet recruiting --> Recruiting In both the StiL and BRIGHT trials, a head-to-head comparison of R-CHOP vs. bendamustine + rituximab (BR) demonstrated superior outcomes with BR with a lower toxicity than R-CHOP.2,3 Attempts to improve on bendamustine-containing chemotherapy with the second-generation monoclonal antibody obinutuzumab, as tested in the GALLIUM trial, improved complete remission rates but resulted in fairly significant myelosuppression and a higher incidence of infection...5 In terms of
  • ||||||||||  Novel Approaches to Richter Syndrome (LEVEL 3, GENERAL ASSEMBLY) -  Jul 5, 2024 - Abstract #SOHO2024SOHO_193;    
    P1/2, P2
    Trials are also ongoing with bispecific antibodies, such as the CD20-directed CD3 T-cell engagers, epcoritamab (NCT04623541),14 glofitamab (NCT06043674), and mosunetuzumab (NCT05207670),15 which, like CAR-T therapy, have all shown efficacy in standard DLBCL. As evidenced, significant efforts employing a multifaceted array of approaches are underway for the treatment of RS, generating hope for the possibility of improved outcomes for this aggressive disease.
  • ||||||||||  Review, Journal:  The value of bispecific antibodies in relapsed and refractory DLBCL. (Pubmed Central) -  May 30, 2024   
    This review discusses the background clinical need, mechanism of action, and clinical data including efficacy and toxicity for bispecific antibodies in DLBCL, focusing on the most advanced class in development; CD20 targeting T-cell engaging antibodies. Emerging possibilities for future use of bispecific antibodies is also discussed, including novel and cytotoxic combination regimens in relapsed and first-line settings.
  • ||||||||||  Columvi (glofitamab-gxbm) / Roche, odronextamab (REGN1979) / Regeneron, Lunsumio (mosunetuzumab-axgb) / Roche, Biogen
    Review, Journal:  Bispecific antibodies in the treatment of Relapsed/Refractory large B-cell lymphoma. (Pubmed Central) -  May 29, 2024   
    These drugs provide a highly efficacious and relatively safe treatment option for patients with highly pre-treated disease including relapse after cellular immunotherapies. In addition, these BsAbs provide a platform for chemotherapy-free regimen for older/frail patients.
  • ||||||||||  Lunsumio (mosunetuzumab-axgb) / Roche
    Trial completion date, Trial primary completion date:  Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma (clinicaltrials.gov) -  May 21, 2024   
    P1,  N=15, Recruiting, 
    Initiation date: Sep 2024 --> May 2024 Trial completion date: Jun 2027 --> Jun 2029 | Trial primary completion date: Jul 2025 --> Jul 2027
  • ||||||||||  Journal:  A pivotal decade for bispecific antibodies? (Pubmed Central) -  Mar 15, 2024   
    Notably, of the 13 currently approved bsAbs, two, emicizumab and faricimab, have achieved blockbuster status, showing the promise of this novel class of therapeutics. In the 2020s, the approval of additional bsAbs can be expected in hematological malignancies, solid tumors and non-oncology indications, establishing bsAbs as essential part of the therapeutic armamentarium.
  • ||||||||||  Columvi (glofitamab-gxbm) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche, Biogen, Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
    Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL (Section 36) -  Mar 5, 2024 - Abstract #AACR2024AACR_2209;    
    P1
    Increased doses of Lonca in combinations were predicted to have limited additional therapeutic benefit; however, additional cycles of combination treatment were predicted to increase TGI. This model suggests that Lonca doses could be reduced to allow for improved tolerability for longer periods of time, up to the point of maximal benefit, although clinical testing is needed to explore these results.